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Rhesus hemolytic disease of the newborn (RHDN) occurs due to red cell alloimmunization, leading to the production of maternal antibodies which cross the placenta and 
affect the fetus. The most common alloimmunization is of rhesus 
(Rh) type D followed by other non-Rh blood group antigens. 
With the introduction of anti-D immunoprophylaxis in the late 
1960s, the incidence of RHDN has decreased dramatically [1]. 
Improved prenatal treatment with intrauterine transfusions (IUT) 
has further decreased the associated mortality and morbidity [2]. 
Despite these advances, fetal anemia, hydrops, and neonatal 
hyperbilirubinemia are still seen; more so in developing nations, 
where resources and expertise are limited [3,4].
Early postnatal complications include hyperbilirubinemia, 
anemia, cholestasis, and acute bilirubin encephalopathy 
while long-term complications include anemia and adverse 
neurodevelopmental outcome. Management primarily comprises 
intensive phototherapy (PT), exchange transfusion (ET), and 
top-up transfusions for late-onset anemia. Besides these, the use of 
immunoglobulins has altered the clinical course of RHDN. Studies 
evaluating postnatal outcomes in Rh-negative isoimmunized 
infants from developing countries are limited [5-7]. This study 
was conducted with the aim to describe the outcomes of newborns 
affected by RHDN at a tertiary care center in North India.
MATERIALS AND METHODS
This was a prospective observational study, conducted in a 20 
bedded neonatology unit of a tertiary care teaching hospital in 
North India from July 2014 to June 2016. All neonates, admitted 
during the study period with RHDN and gestational age at birth 
≥32 weeks, were included in the study. Neonates with maternal 
red cell isoimmunization other than Rh D, presence of other 
comorbidities such as perinatal asphyxia, severe sepsis (based 
on clinical symptoms of infection or positive blood culture) or 
necrotizing enterocolitis, and neonates with gross congenital 
anomalies or syndromic disorders were excluded from the study.
The study was approved by the institute’s ethics committee. 
Written informed consent was obtained from all the participating 
families. Primary outcomes were the duration of PT, need for ET, 
occurrence of late-onset anemia, and need for top-up transfusions. 
Secondary outcomes were conjugated hyperbilirubinemia, 
neurological examination at discharge, and duration of hospital 
stay.
Relevant data were collected in a pre-structured pro forma. 
Neonates were managed for jaundice, anemia, or any other acute 
problem as per standard protocol. The American Academy of 
Pediatrics (AAP) charts  for  neonates  ≥35 weeks  gestation  and 
weight-based PT charts for preterm babies <35 weeks were used 
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for guiding the management of hyperbilirubinemia [8,9]. Intensive 
PT was administered through blue light-emitting diode (LED) PT 
devices (Make – Phoenix LED PT) at a distance of 30–45 cm 
from the bed surface with irradiance of at least 30 µW/cm2/nm.
Indications for ET were cord hematocrit (Hct) <30% or cord 
total serum bilirubin (TSB) >5 mg/dl; rate of rise of TSB>1 mg/
dl/h despite intensive PT; any TSB >12 mg/dl in the first 24 h and 
TSB >20 mg/dl in the neonatal period and TSB in double volume 
exchange  transfusion  zone  as  per  AAP  charts  for  ≥35  weeks 
or weight based charts for 32–35 weeks gestation; presence of 
hydrops at birth or history of previous sibling requiring exchange 
because of Rh isoimmunisation and index patient is born with 
pallor, hepatosplenomegaly and positive DCT. ET was performed 
using freshly collected (<7 days) compatible packed red blood 
cells and plasma that was reconstituted in the blood bank and 
irradiated and leukoreduced before the procedure. Intravenous 
immunoglobulin (IvIg) was given to patients with severe 
hemolysis when TSB approached exchange zone as per AAP.
Following discharge from NICU, neonates received folic acid 
supplementation and were followed up for late-onset anemia and 
conjugated hyperbilirubinemia. Late-onset anemia was defined as 
anemia (Hct <30%) occurring after the 1st week of life. Hct was 
monitored weekly after discharge until 1 month, fortnightly until 
3 months of age, and then monthly for the first 6 months of life. 
Top-up  transfusions were  given when  the Hct was  <20% with 
reticulocyte count <2% in an asymptomatic neonate or at higher 
levels if clinical symptoms of anemia (congestive cardiac failure, 
lethargy, feeding problems, or failure to thrive) were present. For 
conjugated hyperbilirubinemia, total and direct bilirubin fractions 
were monitored fortnightly after discharge until 3 months of age 
and a direct fraction >20% of total was considered as conjugated 
jaundice (cholestasis).
Data were analyzed using SPSS statistics version 17.0. 
Descriptive data were expressed as median with interquartile 
range (IQR) for continuous data or as frequency (percentage) for 
categorical data. Association between variables was tested using 
Spearman correlation coefficient.
RESULTS
A total of 683 neonates were admitted during the study period; 44 
Rh-positive neonates born to Rh-negative mothers were admitted 
during the study period. Of these, eight were non-isoimmunized, 
one was isoimmunized due to anti-M antibody, and two were 
lost to follow-up. Thus, 33 neonates were included for analysis. 
Baseline characteristics and laboratory parameters are shown in 
Tables 1 and 2. Outcomes are shown in Table 3.
Overall, the median duration of PT was 138 h (IQR 64–188) 
with the median maximum bilirubin on PT of 13.7 mg/dl 
(IQR 10.8–14.8). As the number of IUTs increased, the duration 
of PT decreased (Spearman correlation coefficient −0.46; p=0.02). 
A  total  of  14  (42.4%)  neonates  required  at  least  one  ET;  only 
one  required  two ETs. Most  (12  [85.7%]) ETs were performed 
within the first 12 h of life with median age at the first ET of 10 h 
(IQR 9–12). No correlation was found between the number of 
IUTs and ET use (Spearman correlation coefficient 0.22; p=0.28).
Late-onset anemia was seen in 25 (75.7%) newborns; 17 (51.5%) 
required at least one top-up transfusion. The median number of 
top-up  transfusions was  1  (IQR  0–1)  and most  (13  [76.4%])  of 
them were done within the first 6 weeks of life. No correlation was 
seen between reticulocyte count at birth and top-up transfusions 
Table 1: Baseline characteristics of the study population (n=33)
Variables Median (interquartile range)/N (%)
Gestational age at 
birth (weeks) 
36 (35+4–36+5)
Birth weight (g) 2670 (2380–2865)
Male gender 16 (51.5)
Antenatal indirect 
Coombs test titer
1:64 (1:16–1:112)
Fetal intrauterine 
transfusion
25 (75.8)
Number of intrauterine 
transfusions 
2 (3–4)
Mode of delivery
Cesarean section
Vaginal
21 (63.6)
12 (36.3)
Intravenous 
immunoglobulin use
17 (51.5)
Table 2: Laboratory parameters in the study population (n=33)
Variables Median (interquartile range)/N (%)
Cord blood hematocrit at 
birth (%)
40 (37.2–46.2)
Cord blood total 
bilirubin (mg/dl)
3.9 (3.2–5.4)
Cord blood reticulocyte 
count (%)
2.9 (0.2–5.2)
Cord blood positive direct 
antiglobulin test
18 (54.5)
Maximum total bilirubin 
on phototherapy (mg/dl)
13.7 (10.8–14.8)
Table 3: Clinical outcomes in the study population (n=33)
Outcome Median (interquartile range)/N (%)
Duration of phototherapy 138 (64–188)
Neonates requiring 
exchange transfusion 
14 (42.4)
Presence of late-onset 
anemia 
25 (75.7)
Need for top-up transfusion 17 (51.5)
Number of top-up 
transfusions (n)
1 (0–2)
Development of conjugated 
hyperbilirubinemia
5 (15.1)
Neurological examination at discharge
Normal
Tone abnormalities
31 (93.9)
2 (6.1)
Duration of hospital 
stay (days)
14 (11–16)
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(Spearman  correlation  coefficient  −0.20;  p=0.26).  Similarly,  no 
association was seen between the use of either IUT or ET and 
top-up transfusions. Trend of Hct within the first 6 months of life 
showed nadir around 6 weeks of age as shown in Fig. 1.
Conjugated  hyperbilirubinemia  was  seen  in  5  (15.1%) 
neonates and was unrelated to IUT number. Cholestasis was mild 
and transient in three neonates while two required choleretics. The 
median duration of hospital stay was 14 days (IQR 11–16). There 
was no mortality until discharge. Neurological examination at 
discharge was normal in 31 neonates; two had tone abnormalities.
DISCUSSION
As mortality due to RHDN is declining with the advent of Rh 
immunoprophylaxis, attention is shifting toward morbidities 
associated with it. Neonates still require intensive care admissions 
for the management of complications. This study showed that 
hyperbilirubinemia in neonatal period requires intensive PT and 
was related to IUT number. Fetal transfusions are indicated in 
affected fetuses with severe hemolysis which leads to anemia. 
IUTs result in replacement of fetal red blood cells by donor 
Rh-negative red cells which may result in less active hemolysis 
and thus less severe hyperbilirubinemia. The finding of decreased 
PT duration with an increased number of IUTs supports this 
hypothesis and is similar to other studies [10,11].
ET was performed in 42.4% of neonates and was unrelated to 
the number of IUT; results are similar to that described in other 
studies [10-16]. The possible reasons for significant rate of ET 
in our study can be explained by the persistence of hemolysis 
despite IUT and the use of strict early criteria of ET in Rh 
isoimmunization. Most of the ETs were performed within the first 
12 h of life which is similar to reports by De Boer et al. [11] and 
signifies aggressive approach used in our unit for management, as 
well as early criteria for ET.
Three-fourth of the neonates developed late-onset anemia 
and more than half required at least one top-up transfusion. 
The possible reasons could be low-grade ongoing hemolysis, 
erythropoiesis suppression due to IUT or IvIg use, shortened life 
span of donor adult red cells, and persistence of anti-D antibodies 
in the bone marrow which destroy erythroid precursors [17-20]. 
The study did not find any correlation of the use of IUT, ET, or 
reticulocyte count with top-up transfusions. Published literature 
is inconsistent with some studies favoring association of IUT, ET, 
or reticulocyte count with more top-up transfusions [11,16,19,21] 
while others show no association [7,22].
The occurrence of cholestatic jaundice in our study cohort was 
15% which  is  comparable  to  the  published  studies  [7,23]. The 
likely mechanisms include inspissation of bile pigment causing 
stasis and blocking of bile canaliculi, liver damage due to iron 
overload, and hypoxic injury due to anemia.
This prospective study is one of the few studies [5,7,16] 
describing postnatal outcomes in RHDN from a developing 
country. The study also describes the trends of Hct in the first 
6 months of life which has not been reported previously. With 
Figure 1: Trend of median hematocrit levels in the study population
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RHDN still persisting in many countries, it is important to know 
about current outcomes so as to plan optimal management and 
follow-up. Our  study  provides  recent  data  from  India  to  assist 
further research on this topic. There are a few limitations of this 
study. The study has small sample size which could be due to 
overall decreased incidence of RHDN. Further, we have not 
studied the long-term morbidities including neurodevelopmental 
outcomes.
CONCLUSIONS
Short-term morbidities requiring intensive care in neonates 
affected by RHDN are common. They include hyperbilirubinemia 
needing PT and ET, late-onset anemia necessitating top-up 
transfusions, cholestasis, and considerable hospital stay. There 
is a need for further research in this disease which is cause of 
significant morbidities in affected neonates. Future research areas 
include indications for ET, optimal PT, role of IvIg, cost of care, 
and long-term morbidities in RHDN.
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